Investigation of the Accuracy of an Automated Refractor to Provide Well-tolerated Eyeglass Prescriptions
Launched by PLENOPTIKA, INC. · Mar 12, 2025
Trial Information
Current as of May 09, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • who have had an eye exam at the NECO Center for Eye Care of Commonwealth or Roslindale
- • who are aged between 18 years and 65 years
- Exclusion Criteria:
- • whose refractive error is outside of the detection range of the QuickSee Free Pro and QuickSee Plus devices: -13 D to +10 D (S) and -8 D to + 8 D (C)
- • who are unable to provide consent
- • who have undergone any eye surgery
- • who have a history of ocular disease
- • who are taking systemic drugs
- • who wear more than one pair of single vision eyeglasses for distance
- • who more than occasionally wear soft contact lenses
- • who are unable and unwilling to wear the eyeglasses provided by the study for the required duration
About Plenoptika, Inc.
Plenoptika, Inc. is an innovative biotechnology company dedicated to transforming the landscape of ocular health through advanced imaging technologies and therapeutic solutions. With a focus on developing cutting-edge diagnostic tools and treatment options for vision-related diseases, Plenoptika harnesses the power of precision medicine to enhance patient outcomes. Committed to rigorous clinical research and collaboration with leading healthcare professionals, the company aims to address unmet needs in ophthalmology and improve the quality of life for individuals with visual impairments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Boston, Massachusetts, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported